Please use this identifier to cite or link to this item: http://hdl.handle.net/1822/58207

TitleCrotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines
Author(s)Muller, Silvana Pinotti
Silva, Viviane Aline Oliveira
Silvestrini, Ana Vitória Pupo
de Macedo, Luana Henrique
Caetano, Guilherme Ferreira
Reis, R. M.
Mazzi, Mauricio Ventura
KeywordsAmino Acid Sequence
Animals
Antineoplastic Agents
Apoptosis
Cell Cycle
Cell Death
Cell Line, Tumor
Cell Survival
Crotalus
Crotoxin
HeLa Cells
Humans
Inhibitory Concentration 50
Mice
NIH 3T3 Cells
Neoplasms
Phospholipases A2
Snake venom
Cytotoxicity
Antitumor
Glioma
Pancreas
Issue date15-Dec-2018
PublisherPergamon-Elsevier Science Ltd
JournalToxicon
CitationMuller, S. P., Silva, V. A. O., Silvestrini, A. V. P., de Macedo, L. H., Caetano, G. F., Reis, R. M., & Mazzi, M. V. (2018). Crotoxin from Crotalus durissus terrificus venom: In vitro cytotoxic activity of a heterodimeric phospholipase A2 on human cancer-derived cell lines. Toxicon, 156, 13-22
Abstract(s)Crotoxin (CTX), a heterodimeric phospholipase present in venom of snakes of the genus Crotalus, has demonstrated a broad spectrum of pharmacological properties, such as antimicrobial, hemostatic, and antitumoral. However, the precise mechanism of its cytotoxicity and antitumoral properties remains to be determined. Therefore, in the present study, we isolated crotoxin (F1 CTX) through two steps DEAE-Sepharose and Heparin-Sepharose FF chromatography. The C-terminal sequence of the A- and B-chain protein fragment was determined by LC-MS/MS mass spectrometry, which showed 100% identity to crotoxin structure. In order to investigate its cytotoxic effects, we demonstrated that the F1 CTX fraction at 0-30 μg/mL concentrations for 72 h presented a heterogeneous response profile on nine human cancer-derived cell lines from four tumor types (pancreatic, esophagus, cervical cancer, and glioma). The glioma (GAMG and HCB151) and pancreatic (PSN-1 and PANC-1) cancer cells showed a higher sensitivity with IC50 of <0.5, 4.1, 0.7 and < 0.5 μg/mL, respectively. Conversely, F1 CTX does not reduce the viability of normal cells. On the other hand, cervical (SiHa) and esophagus (KYSE270) cancer cell lines presented higher resistance, with IC50 higher than 30.2 and 8.7 μg/mL, respectively. Moreover, F1 CTX did not affect cell cycle distribution under the conditions evaluated and seems to be more cytotoxic than cytostatic. The pro-apoptotic effect of F1 CTX treatment was demonstrated in glioma (HCB151) cell line. In addition, crotoxin revealed a potential to initiate cell responses such as DNA damage in glioma (HCB151) and pancreatic cancer by H2AX activity induction. Conversely, F1 CTX does not reduce the viability of normal cells. Importantly, the comparison of F1 CTX effect with standard chemotherapeutic agents demonstrated a greater cytotoxic potential in the majority of tumor types (glioma, pancreatic, and cervical cancer). On the other hand, F1 CTX was less cytotoxic in esophageal cell lines compared to the gemcitabine agent used in clinical practice. Therefore, this work showed that F1 CTX has a cytotoxic activity and pro-apoptotic potential, contributing to the knowledge about the F1 crotoxin properties as well as its possible use in cancer research, particularly in glioma and pancreatic cancer cell lines.
TypeArticle
DescriptionAccepted manuscript
URIhttp://hdl.handle.net/1822/58207
DOI10.1016/j.toxicon.2018.10.306
ISSN0041-0101
e-ISSN1879-3150
Publisher versionhttps://www.sciencedirect.com/science/article/pii/S0041010118307141
Peer-Reviewedyes
AccessOpen access
Appears in Collections:ICVS - Artigos em revistas internacionais / Papers in international journals

Files in This Item:
File Description SizeFormat 
muller2018.pdf4,24 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID